MERCADO DE MEDICAMENTOS ANTIDIABETES ORALES: CRECIMIENTO, TENDENCIAS, IMPACTO DE COVID-19 Y PRONÓSTICOS (2022 - 2027)

El mercado de Medicamentos orales contra la diabetes está segmentado por Medicamentos (biguanidas, inhibidores de la alfa-glucosidasa, agonistas del receptor de dopamina-D2, inhibidor del cotransporte de sodio-glucosa -2 (SGLT-2), inhibidores de la dipeptidil peptidasa - 4 (DPP-4), sulfonilureas y Meglitinidas), y Geografía.

Instantánea del mercado

 Oral Anti-diabetes Drugs Market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >4 %
 Oral Anti-diabetes Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Visión general del mercado

Se estima que el mercado de medicamentos orales contra la diabetes superó los 39 200 millones de USD en 2019 y está creciendo debido al aumento de la población con diabetes tipo 2. El crecimiento significativo en el mercado se puede atribuir a factores tales como el aumento de la prevalencia de la diabetes y el creciente número de programas iniciados por diversas organizaciones de salud relacionados con la concienciación sobre la salud. En 2019, se estimó que de 511 millones de personas que padecían diabetes, el 31,3 % no estaban diagnosticadas. En 2019, la diabetes fue la causa de 4,2 millones de muertes al año, lo que la convierte en la octava causa de muerte en todo el mundo. La condición diabética, en general, duplica el riesgo de muerte. Actualmente, alrededor del 10 % de todos los casos de diabetes son de tipo 1 y el resto son de tipo 2. Por lo tanto, 

Alcance del Informe

Se ha llevado a cabo un estudio holístico del mercado mediante la incorporación de varios factores, que van desde las condiciones demográficas y los ciclos económicos específicos de cada país hasta las influencias macroeconómicas específicas del mercado que se necesitan para analizar las tendencias futuras. La investigación descubre muchos cambios de paradigma en el mercado estudiado, en términos de dinámica de mercado a nivel de marca. El mercado de fármacos antidiabéticos orales está segmentado por fármacos (biguanidas, inhibidores de la alfa-glucosidasa, agonistas del receptor de dopamina-D2, inhibidor del cotransporte de sodio-glucosa -2 (SGLT-2), inhibidores de la dipeptidil peptidasa - 4 (DPP-4), sulfonilureas y meglitinidas) y geografía.

By Drug (Value and Volume 2012-2025)
Biguanides
Metformins
Alpha-glucosidase inhibitors
Alpha-glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Geography
North America
United States (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Canada (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of North America (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Europe
France (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Germany (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Italy (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Spain (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
United Kingdom (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Russia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Europe (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Latin America
Mexico (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Brazil (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Latin America (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Asia-Pacific
Japan (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
South Korea (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
China (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
India (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Australia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Vietnam (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Malaysia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Indonesia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Philippines (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Thailand (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Asia-Pacific (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Middle-East and Africa
Saudi Arabia (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Iran (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Egypt (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Oman (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
South Africa (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Middle-East and Africa (Value and Volume 2012-2025)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

Report scope can be customized per your requirements. Click here.

Tendencias clave del mercado

El segmento de inhibidores DPP-4 tuvo la mayor cuota de mercado en 2019

El segmento de inhibidores de la dipeptidil peptidasa - 4 (DPP-4) del mercado de medicamentos orales contra la diabetes se valoró en más de USD 7 millones en 2019, y se espera que registre una CAGR inferior al 4% durante el período de pronóstico (2019- 2025). Los medicamentos inhibidores de la DPP-4 están cobrando impulso en el mercado porque los productos no parecen tener ningún efecto sobre los resultados cardiovasculares adversos primarios y el riesgo de insuficiencia cardíaca. Además, se pueden utilizar tanto como terapia combinada con insulina, sulfonilureas y fármacos dipeptidil peptidasa-4 como en monoterapia, lo que los convierte en una clase de fármacos ampliamente utilizada. Durante el período de pronóstico, se espera que el segmento de los inhibidores de DPP-4 experimente una tasa de crecimiento constante, debido a la introducción de nuevos medicamentos que han mejorado la eficacia, como el péptido similar al glucagón (GLP-1) y el cotransportador de sodio-glucosa-2. (SGLT-2) inhibidores.

 Oral Anti-diabetes Drugs Market Key Trends

Asia-Pacífico liderando el mercado de medicamentos orales contra la diabetes

Actualmente, América del Norte tiene la mayor participación en el mercado de medicamentos orales contra la diabetes. Sin embargo, se espera que Asia-Pacífico experimente la mayor tasa de crecimiento durante el período de pronóstico. Esto se debe a la alta prevalencia de diabetes en esta región, lo que provocó las consiguientes consecuencias adversas para la salud y la economía. Las tasas de casos recién diagnosticados de diabetes tipo 1 y tipo 2 están aumentando entre los jóvenes de la región de Asia-Pacífico. En 2019, en China e India, alrededor de 123,6 millones de personas y 76,79 millones de personas, respectivamente, viven con diabetes diagnosticada. Además, se espera que un aumento en el lanzamiento de nuevos medicamentos con eficacia mejorada y un alto reembolso por medicamentos tenga un impacto positivo en el mercado de medicamentos orales contra la diabetes.

 Oral Anti-diabetes Drugs Market Growth by Region

Panorama competitivo

El mercado de medicamentos antidiabéticos orales está consolidado, con pocos fabricantes importantes que tengan presencia en el mercado global, mientras que los fabricantes restantes están confinados a otros mercados locales o regionales. Las empresas se están centrando en las innovaciones en medicamentos para la diabetes. Por ejemplo, Oramed está investigando la nueva molécula ORMD-0801, que es la primera cápsula de insulina oral que tiene la forma más conveniente y segura de administrar la terapia con insulina. Se espera que este medicamento cambie las reglas del juego en los mercados de insulina y medicamentos orales contra la diabetes.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug (Value and Volume 2012-2025)

      1. 5.1.1 Biguanides

        1. 5.1.1.1 Metformins

      2. 5.1.2 Alpha-glucosidase inhibitors

        1. 5.1.2.1 Alpha-glucosidase Inhibitors

      3. 5.1.3 Dopamine -D2 Receptor Agonist

        1. 5.1.3.1 Bromocriptin (Cycloset)

      4. 5.1.4 Sodium-glucose Cotransport -2 (SGLT-2) inhibitor

        1. 5.1.4.1 Invokana (Canagliflozin)

        2. 5.1.4.2 Jardiance (Empagliflozin)

        3. 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 5.1.4.4 Suglat (Ipragliflozin)

      5. 5.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

        1. 5.1.5.1 Januvia (Sitagliptin)

        2. 5.1.5.2 Onglyza (Saxagliptin)

        3. 5.1.5.3 Tradjenta (Linagliptin)

        4. 5.1.5.4 Vipidia/Nesina (Alogliptin)

        5. 5.1.5.5 Galvus (Vildagliptin)

      6. 5.1.6 Sulfonylureas

        1. 5.1.6.1 Sulfonylureas

      7. 5.1.7 Meglitinides

        1. 5.1.7.1 Meglitinides

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2012-2025)

          1. 5.2.1.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.1.2 Canada (Value and Volume 2012-2025)

          1. 5.2.1.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.1.3 Rest of North America (Value and Volume 2012-2025)

          1. 5.2.1.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2012-2025)

          1. 5.2.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.2.2 Germany (Value and Volume 2012-2025)

          1. 5.2.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.2.3 Italy (Value and Volume 2012-2025)

          1. 5.2.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        4. 5.2.2.4 Spain (Value and Volume 2012-2025)

          1. 5.2.2.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        5. 5.2.2.5 United Kingdom (Value and Volume 2012-2025)

          1. 5.2.2.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        6. 5.2.2.6 Russia (Value and Volume 2012-2025)

          1. 5.2.2.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        7. 5.2.2.7 Rest of Europe (Value and Volume 2012-2025)

          1. 5.2.2.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2012-2025)

          1. 5.2.3.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.3.2 Brazil (Value and Volume 2012-2025)

          1. 5.2.3.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2012-2025)

          1. 5.2.3.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2012-2025)

          1. 5.2.4.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.4.2 South Korea (Value and Volume 2012-2025)

          1. 5.2.4.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.4.3 China (Value and Volume 2012-2025)

          1. 5.2.4.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        4. 5.2.4.4 India (Value and Volume 2012-2025)

          1. 5.2.4.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        5. 5.2.4.5 Australia (Value and Volume 2012-2025)

          1. 5.2.4.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        6. 5.2.4.6 Vietnam (Value and Volume 2012-2025)

          1. 5.2.4.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        7. 5.2.4.7 Malaysia (Value and Volume 2012-2025)

          1. 5.2.4.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        8. 5.2.4.8 Indonesia (Value and Volume 2012-2025)

          1. 5.2.4.8.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        9. 5.2.4.9 Philippines (Value and Volume 2012-2025)

          1. 5.2.4.9.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        10. 5.2.4.10 Thailand (Value and Volume 2012-2025)

          1. 5.2.4.10.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2025)

          1. 5.2.4.11.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2012-2025)

          1. 5.2.5.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        2. 5.2.5.2 Iran (Value and Volume 2012-2025)

          1. 5.2.5.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        3. 5.2.5.3 Egypt (Value and Volume 2012-2025)

          1. 5.2.5.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        4. 5.2.5.4 Oman (Value and Volume 2012-2025)

          1. 5.2.5.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        5. 5.2.5.5 South Africa (Value and Volume 2012-2025)

          1. 5.2.5.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume 2012-2025)

          1. 5.2.5.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2025)

    2. 6.2 Type 2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Sanofi S.A.

      2. 7.1.2 Eli Lilly and Company

      3. 7.1.3 AstraZeneca plc

      4. 7.1.4 Astellas Pharma Inc.

      5. 7.1.5 Johnson & Johnson (Janssen Pharmaceuticals)

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Merck And Co.

      8. 7.1.8 Takeda

      9. 7.1.9 Bristol Myers Squibb

      10. 7.1.10 Novartis

      11. 7.1.11 Pfizer

    2. 7.2 Company Share Analysis

      1. 7.2.1 Sanofi S.A.

      2. 7.2.2 Eli Lilly and Company

      3. 7.2.3 AstraZeneca plc

      4. 7.2.4 Astellas Pharma Inc.

      5. 7.2.5 Johnson & Johnson (Janssen Pharmaceuticals)

      6. 7.2.6 Merck and Co.

      7. 7.2.7 Other Companies Analysis

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

El mercado de mercado de medicamentos orales contra la diabetes se estudia desde 2016 hasta 2027.

El mercado de medicamentos orales contra la diabetes está creciendo a una CAGR de >4% en los próximos 5 años.

Asia Pacífico está creciendo a la CAGR más alta durante 2021-2026.

América del Norte tiene la participación más alta en 2021.

Eli Lilly and Company, Johnson & Johnson (Janssen Pharmaceuticals), Astellas Pharma Inc., AstraZeneca plc, Sanofi SA son las principales empresas que operan en el mercado de medicamentos orales contra la diabetes.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!